Article Text

PDF
Can we prescribe TMP/SMX prophylaxis without any concerns equally for all patients with rheumatic disease?
  1. Yasuhiro Suyama1,2,
  2. Masato Okada2
  1. 1Division of Rheumatology, JR Tokyo General Hospital, Tokyo, Japan
  2. 2Immuno-Rheumatology Center, St. Luke’s International Hospital, St. Luke’s International University, Tokyo, Japan
  1. Correspondence to Dr Yasuhiro Suyama, Immuno-Rheumatology Center, St. Luke’s International Hospital, St. Luke’s International University, Tokyo, Japan; y-suyama{at}jreast.co.jp

Statistics from Altmetric.com

We read with great interest the recent article by Park et al1 and appreciate the authors’ efforts to assess the benefit and safety of trimethoprim-sulfamethoxazole (TMP/SMX) as primary prophylaxis for pneumocystis pneumonia in patients with rheumatic diseases, exposed to prolonged high-dose glucocorticoids.

However, we would like to point out one concern in the incidence of …

View Full Text

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

Linked Articles